Harrow Inc (HROW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HROW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1096)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HROW's Discussions on Twitter

Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HROW Harrow Inc	42.48	1.58B	272.30M	-5.14M	42.76M	-0.1635
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Harrow Inc Stock (HROW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-11	Eingeleitet	Cantor Fitzgerald	Overweight
2025-06-12	Eingeleitet	BTIG Research	Buy
2025-06-10	Eingeleitet	William Blair	Outperform
2025-02-06	Eingeleitet	H.C. Wainwright	Buy
2024-12-04	Bestätigt	B. Riley Securities	Buy
2024-04-11	Eingeleitet	Craig Hallum	Buy
2022-09-08	Fortgesetzt	B. Riley Securities	Buy
2021-10-14	Fortgesetzt	B. Riley Securities	Buy
2021-09-24	Eingeleitet	Aegis Capital	Buy
2021-07-02	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Harrow Inc Aktie (HROW) Neueste Nachrichten

Finanzdaten der Harrow Inc-Aktie (HROW)

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc Aktie (HROW) Neueste Nachrichten

Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛

HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et

HROW News | HARROW INC (NASDAQ:HROW) - ChartMill

Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare

Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm

Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo

Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com

Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus

Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus

A first FDA-approved eye biosimilar returns to U.S. sales - Stock Titan

A Look at Harrow Inc (HROW) After 3.2% Gain -- GF Value $42.31 v - GuruFocus

Cantor Fitzgerald Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $88 - Moomoo

Harrow, Inc. Actuals & Estimates (NASDAQ:HROW) - TradingView

HROW Forecast — Price Target — Prediction for 2027 - TradingView

How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices - simplywall.st

Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 - Insider Monkey

Form 4 Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia

[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan

Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant - Stock Titan

Harrow (HROW) director granted 5,248 restricted stock units as compensation - Stock Titan

Form 8K Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia

Harrow elects directors and approves executive compensation at annual meeting - Investing.com

Harrow, Inc. (NASDAQ: HROW) 2026 Annual Meeting Results: Shareholder Votes and Key Decisions from Form 8-K Filing – Minichart - Minichart

Harrow (HROW) investors back all 2026 director, pay and auditor proposals - Stock Titan

Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

$Harrow (HROW.US)$ i shouldve put more in - Moomoo

Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing - simplywall.st

Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey

Harrow Inc (HROW) Institutional Confidence - TradingKey

Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Insider Monkey

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy? - Yahoo Finance

Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView

HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire

Finanzdaten der Harrow Inc-Aktie (HROW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HROW